中国麻风皮肤病杂志 ›› 2020, Vol. 36 ›› Issue (10): 631-635.doi: 10.12144/zgmfskin202010631

• 综述 • 上一篇    下一篇

朗格汉斯细胞在特应性皮炎免疫机制和治疗中的作用

朱晨曦,姚志荣   

  1. 上海市新华医院皮肤科，上海，200092
  • 出版日期:2020-10-15 发布日期:2020-09-24
  • 通讯作者: 姚志荣，E-mail: zryaoxh@sina.com

Update of the role of langerhans cell in the immune mechanism and treatment in atopic dermatitis

ZHU Chenxi, YAO Zhirong   

  1. Department of Dermatology, Shanghai Xinhua Hospital, Shanghai 200092, China
  • Online:2020-10-15 Published:2020-09-24
  • Contact: YAO Zhirong, E-mail: zryaoxh@sina.com

PDF (PC)

422

摘要： 特应性皮炎是一种涉及多种免疫细胞的慢性复发性炎症性皮肤病，朗格汉斯细胞在其发病中起着重要作用。研究表明朗格汉斯细胞在发病早期迁移至皮肤淋巴结，活化并主导Th2型免疫反应。治疗方面，倍他米松、大环内酯类抗生素可以抑制朗格汉斯细胞诱导Th2型炎症，而焦油和组胺4受体拮抗剂则可抑制朗格汉斯细胞表达CCL17和CCL22。本文对朗格汉斯细胞在特应性皮炎免疫机制和治疗中的作用进行了综述。

关键词: 特应性皮炎, 朗格汉斯细胞, 免疫反应, 丝聚蛋白

Abstract: Atopic dermatitis is a chronic relapsing inflammatory skin disease that involves a variety of immune cells. The langerhans cell plays an important role in starting and maintaining the disease. The migration of langerhans cell to the skin lymph nodes happens at the early stage of the dermatitis, and then, it gets activated and leads to Th2 type immunoreaction. In terms of treatment, betamethasone and macrolide antibiotics can inhibit langerhans cell-induced Th2-type inflammation. Tar and histamine 4 receptor antagonists can inhibit the expression of CCL17 and CCL22 by langerhans cell. The update of the role of langerhans cell in the immune mechanism and treatment in atopic dermatitis is reviewed in this paper.

Key words: atopic dermatitis, langerhans cells, immune response, filaggrin